©The Author(s) 2025.
World J Clin Oncol. Oct 24, 2025; 16(10): 112097
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.112097
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.112097
Figure 3 Elevated levels of inflammatory cytokines in cisplatin-resistant non-small cell lung cancer cells.
A-E: Enzyme-linked immunosorbent assay was utilized to detect the levels of interleukin (IL)-6 (A), IL-8 (B), tumor necrosis factor-α (C), IL-10 (D) and IL-4 (E) in the supernatant of the cell culture medium. Data were presented as mean ± SD (n = 3). aP < 0.05 vs A549; bP < 0.05, cP < 0.01 vs SK-MES-1. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. IL: Interleukin; TNF-α: Tumor necrosis factor-α; DDP: Cisplatin.
- Citation: Dai Y, Liu YY, Cao N, Tian XW, Feng J, Hu ZZ, Xu JQ. Overcoming chemoresistance in non-small cell lung cancer: Insights into the influence of inflammatory factors on treatment response. World J Clin Oncol 2025; 16(10): 112097
- URL: https://www.wjgnet.com/2218-4333/full/v16/i10/112097.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i10.112097